Cardiovascular Heart Rate

Beating More Than Just Heart Disease


For millions of people around the world, the chances of suffering from a stroke or heart attack is a looming threat – and great concern. With an estimated 19.1 million deaths from cardiovascular diseases in 2020, it’s easy to see why.1 Major behavioral risk factors such as tobacco use, unhealthy diet, physical inactivity, and harmful use of alcohol are leading causes of treatable cardiovascular diseases. However, even with the achievement of target LDL-C levels, millions of patients still have a significant and persistent risk of cardiovascular events, especially patients with elevated triglycerides.At Amarin, it is our mission to stop cardiovascular disease from being a leading cause of death, by providing our patients, doctors and investors with reliable CV treatment options.

Cardiovascular System

The first step in better cardiometabolic health

Cardiovascular disease (CVD) is a major health problem, affecting millions of people globally. From hereditary conditions and lifestyle habits to societal and environmental contexts, our hearts face many concerns.

While a healthy lifestyle may slow down the progression of CVD, sometimes, more needs to be done. If necessary, your doctor may decide that lifestyle changes need to be augmented with other treatment options, to reduce elevated low-density lipoprotein cholesterol (LDL-C) levels.However, despite appropriate interventions, many patients' heart health may remain at risk.

This is why our ambition at Amarin is to be a part of the solution in addressing this important health issue. Always consult with your healthcare professional who is best placed to advise on any personal medical matters.


For medical questions, updated publications, information about our products or any other medical information, please submit your details here ► and a member of our Medical Affairs team will respond to you.


Medical Professional Examine Lab


Making breakthroughs that change the world.

At Amarin, we’re committed to providing breakthrough treatments, scientific understanding and expertise.

Breaker Flask Chemicals


Bold science for cardiovascular health

Learn about our approved product.


  1. Cardiovascular Diseases (Cvds). World Health Organization, World Health Organization,
  2. Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.
  3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188.
ALL-NP-00022 1/23